Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7591 to 7605 of 8213 results

  1. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

  2. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    In development Reference number: GID-TA11663 Expected publication date: TBC

  3. Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)

    This guidance has been updated and replaced by NICE interventional procedures guidance 807, 808 and 810.

  4. myCOPD for managing chronic obstructive pulmonary disease (MTG68)

    This guidance has been updated and replaced by NICE healthtech guidance 736, which covers using myCOPD for self-management of chronic obstructure pulmonary disease (COPD), and NICE healthtech guidance 718, which covers using myCOPD for pulmonary rehabilitation.

  5. Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease (MIB300)

    This advice has been updated and replaced by NICE healthtech guidance 736.

  6. Artificial intelligence for analysing chest X-ray images (MIB292)

    This medtech innovation briefing has been updated and replaced by HealthTech guidance 696

  7. Space from Depression for treating adults with depression (MIB215)

    This advice has been updated and replaced by NICE HealthTech guidance 675.

  8. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Discontinued Reference number: GID-TA11008

  9. Improving outcomes in urological cancers (CSG2)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.

  10. Improving supportive and palliative care for adults with cancer (CSG4)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.

  11. Improving outcomes in breast cancer (CSG1)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.

  12. Workplace health - older employees

    Discontinued Reference number: GID-PHG59

  13. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development Reference number: GID-TA10858 Expected publication date: TBC

  14. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.  

  15. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    In development Reference number: GID-TA11214 Expected publication date: TBC